

Ventripoint Announces Sponsorship for the 2022 SickKids Echo Symposium

Toronto, Ontario – The Newswire – May 3, 2022 - Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) is pleased to announce that it will be a sponsor for the 2022 SickKids Echo Symposium. The topic of this year's symposium is introduction to cardiac anatomical (morphological) abnormalities in congenital heart disease, how it relates to echocardiographic imaging, and the use of echocardiographic imaging in surgical decision-making in congenital heart disease. The event will take place May 6-8 at the Hospital for Sick Children in Toronto, Ontario. There is expected to be 2000+ attendees.

The 2022 SickKids Symposium aims to improve the knowledge of physicians, surgeons, and sonographers who use echocardiograms in newborn and paediatric patient populations or echocardiographic studies in adults with repaired congenital heart disease. This multi-day event will have educational presentations, discussions, and live scanning that focus on the relationship between cardiac morphology and echocardiographic imaging.

As a sponsor for the event, Ventripoint's logo will be displayed on the conference website and on-screen during scheduled breaks during the weekend courses. There will be an in-person demo of the VMS+, followed by a period for questions about the VMS+ system. This is an excellent opportunity for Ventripoint to educate conference attendees about the capabilities of the VMS+ system, as well as further exposure for those not yet familiar with the system.

Ventripoint is committed to developing cardiac diagnostic tools that provide accurate and reliable measurements of cardiac function. Ventripoint's involvement in the 2022 SickKids Symposium highlights the commitment to supporting effective clinical assessment and diagnosis through education and promotion.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams
gadams@ventripoint.com
519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.